SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy

Table 2

All adverse events regardless of attribution (N = 20 patients).

Adverse events, n (%)	Grade 1	Grade 2	Grade 3	Grade 4
Anemia	1 (5)	4 (20)	5 (25)	1 (5)
Fatigue	5 (25)	5 (25)	3 (15)
Neutropenia			6 (30)	3 (15)
Thrombocytopenia			3 (15)	2 (10)
Peripheral sensory neuropathy	1 (5)		2 (10)
Lymphopenia		1 (5)	2 (10)
Diarrhea	3 (15)		1 (5)
Decreased ejection fraction			1 (5)
Hypokalemia			1 (5)
Pneumonia			1 (5)
Noncardiac chest pain			1 (5)
Pain			1 (5)
Pericardial effusion			1 (5)
Pericardial tamponade			1 (5)
Pericarditis			1 (5)
Pulmonary embolism			1 (5)
Syncope			1 (5)
Vomiting	4 (20)		1 (5)
Leukopenia		1 (5)	2 (10)
Biopsy-related bleeding				1 (5)

Grade 3 pericardial effusion, tamponade, and pericarditis all occurred in the same patient.